Literature DB >> 28302679

Disrupting Androgen Receptor Signaling Induces Snail-Mediated Epithelial-Mesenchymal Plasticity in Prostate Cancer.

Lu Miao1, Lin Yang1,2, Rui Li1, Daniel N Rodrigues3, Mateus Crespo3, Jer-Tsong Hsieh1, Wayne D Tilley4,5, Johann de Bono3, Luke A Selth4,5, Ganesh V Raj6.   

Abstract

Epithelial-to-mesenchymal plasticity (EMP) has been linked to metastasis, stemness, and drug resistance. In prostate cancer, EMP has been associated with both suppression and activation of the androgen receptor (AR) signaling. Here we investigated the effect of the potent AR antagonist enzalutamide on EMP in multiple preclinical models of prostate cancer and patient tissues. Enzalutamide treatment significantly enhanced the expression of EMP drivers (ZEB1, ZEB2, Snail, Twist, and FOXC2) and mesenchymal markers (N-cadherin, fibronectin, and vimentin) in prostate cancer cells, enhanced prostate cancer cell migration, and induced prostate cancer transformation to a spindle, fibroblast-like morphology. Enzalutamide-induced EMP required concomitant suppression of AR signaling and activation of the EMP-promoting transcription factor Snail, as evidenced by both knockdown and overexpression studies. Supporting these findings, AR signaling and Snail expression were inversely correlated in C4-2 xenografts, patient-derived castration-resistant metastases, and clinical samples. For the first time, we elucidate a mechanism explaining the inverse relationship between AR and Snail. Specifically, we found that AR directly repressed SNAI1 gene expression by binding to specific AR-responsive elements within the SNAI1 promoter. Collectively, our findings demonstrate that de-repression of Snail and induction of EMP is an adaptive response to enzalutamide with implications for therapy resistance. Cancer Res; 77(11); 3101-12. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28302679     DOI: 10.1158/0008-5472.CAN-16-2169

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  30 in total

1.  Small molecule JQ1 promotes prostate cancer invasion via BET-independent inactivation of FOXA1.

Authors:  Leiming Wang; Mafei Xu; Chung-Yang Kao; Sophia Y Tsai; Ming-Jer Tsai
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

2.  Androgen receptor (AR) cistrome in prostate differentiation and cancer progression.

Authors:  Fengtian Wang; Hari K Koul
Journal:  Am J Clin Exp Urol       Date:  2017-11-09

3.  Prostate cancer: Enzalutamide promotes mesenchymal plasticity via Snail activation.

Authors:  Peter Sidaway
Journal:  Nat Rev Urol       Date:  2017-04-04       Impact factor: 14.432

4.  Involvement of androgen receptor (AR)/microRNA-21 axis in hypoxia/reoxygenation-induced apoptosis of mouse renal tubular epithelial cells.

Authors:  Tongchang Chen; Qiu Yao; Weichao Wang; Zhenfeng Ye; Yawei Huang; Meng Wu; Xiaoqing Xi
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

5.  A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer.

Authors:  Wassim Abida; Joshi J Alumkal; Rahul R Aggarwal; Michael T Schweizer; David M Nanus; Allan J Pantuck; Elisabeth I Heath; Eric Campeau; Sarah Attwell; Karen Norek; Margo Snyder; Lisa Bauman; Sanjay Lakhotia; Felix Y Feng; Eric J Small
Journal:  Clin Cancer Res       Date:  2020-07-21       Impact factor: 12.531

Review 6.  Resistance to second-generation androgen receptor antagonists in prostate cancer.

Authors:  Keith T Schmidt; Alwin D R Huitema; Cindy H Chau; William D Figg
Journal:  Nat Rev Urol       Date:  2021-03-19       Impact factor: 14.432

7.  Novel Target Opportunities in Non-Metastatic Castrate Resistant Prostate Cancer.

Authors:  Stephanie Gleicher; Baylee A Porter; Disharee Nath; Guanqun Li; Rakesh Khanna; Hanan Goldberg; Marcin Kortylewski; Gennady Bratslavsky; Leszek Kotula
Journal:  Cancers (Basel)       Date:  2021-05-17       Impact factor: 6.639

8.  Combined immunotherapy for advanced prostate cancer: Empowering the T cell army.

Authors:  Sufyan Suleman; Gong-Hong Wei
Journal:  Asian J Urol       Date:  2017-05-10

Review 9.  The Role and Mechanism of Epithelial-to-Mesenchymal Transition in Prostate Cancer Progression.

Authors:  U-Ging Lo; Cheng-Fan Lee; Ming-Shyue Lee; Jer-Tsong Hsieh
Journal:  Int J Mol Sci       Date:  2017-09-30       Impact factor: 5.923

Review 10.  Function of Tumor Suppressors in Resistance to Antiandrogen Therapy and Luminal Epithelial Plasticity of Aggressive Variant Neuroendocrine Prostate Cancers.

Authors:  Rama Soundararajan; Ana M Aparicio; Christopher J Logothetis; Sendurai A Mani; Sankar N Maity
Journal:  Front Oncol       Date:  2018-03-15       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.